Within the first months of the COVID-19 vaccination campaign, previously healthy recipients
who developed severe thrombosis (often cerebral and/or splanchnic vasculature) and …

Heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombotic
thrombocytopenia (VITT) are highly prothrombotic (thrombosis frequency≥ 50%). Both are …

Safety and efficacy of vaccines against the SARS-CoV-2 coronavirus has been
demonstrated in clinical trials and next by their real world use through the course of the …

Kanack and colleagues analyze anti-platelet factor 4 antibodies from 5 patients with vaccine-
induced thrombotic thrombocytopenia (VITT) secondary to COVID-19 adenoviral vaccination …

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but serious adverse
syndrome occurring 5 to 30 days after adenoviral vector COVID-19 vaccination. Therefore, a …

Introduction: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare yet
severe adverse complication first identified during the global vaccination effort against SARS …

Abstract Coronavirus disease-19 (COVID-19) vaccine–induced immune thrombotic
thrombocytopenia (VITT) is a rare but serious clinical condition with high mortality rate in …

Background Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a complication
of adenoviral-based vaccine against SARS-CoV-2 due to prothrombotic immunoglobulin (Ig) …

In late February 2021, a prothrombotic syndrome was encountered for the first time in some
of the recipients of ChAdOx1 CoV‐19 vaccine (AstraZeneca, University of Oxford, and …

This is a revision of the online November 2021 Brighton thrombosis with thrombocytopenia
syndrome (TTS) case definition and a new Brighton Collaboration case definition for vaccine …